Solid Biosciences (SLDB)

• Market cap: $128M
• 1 day: -1.53%
• 5 days: -0.93%
• 1 month: -21.71%
• 3 months: -43.68%
• 6 months: -63.23%
• Year to date: -17.69%
• 1 year: -59.16%
• 5 years: -94.26%
• 10 years: -99.05%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Employees: 88

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,582% more call options, than puts

Call options by funds: $4.51M | Put options by funds: $268K

108% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 13

23% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 22

17% more capital invested

Capital invested by funds: $214M [Q2] → $250M (+$36.3M) [Q3]

15% more funds holding

Funds holding: 80 [Q2] → 92 (+12) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

5.24% less ownership

Funds ownership: 98.13% [Q2] → 92.89% (-5.24%) [Q3]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 274% upside
• Avg. target: $15 367% upside
• High target: $16 398% upside

6 analyst ratings

• positive: 6 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Arthur He 0% 1-year accuracy 0 / 30 met price target	398% upside $16	Buy Reiterated	13 Jan 2025
Truist Securities Joon Lee 50% 1-year accuracy 21 / 42 met price target	398% upside $16	Buy Initiated	8 Jan 2025
Wedbush Laura Chico 26% 1-year accuracy 16 / 61 met price target	398% upside $16	Outperform Initiated	13 Dec 2024
JMP Securities Silvan Tuerkcan 29% 1-year accuracy 16 / 56 met price target	367% upside $15	Market Outperform Initiated	10 Dec 2024
JP Morgan Anupam Rama 19% 1-year accuracy 11 / 59 met price target	274% upside $12	Overweight Maintained	12 Nov 2024